Speeple News Search

Search: |

Tags | Domains | Searches | Statistics | Options | Advanced Search

knowmoremedia.com » Tags » As

Related tags: abbott, drug regulations and approval, emea, eu, humira, parkinson s, ra, research, research and development, schering plough corporation

  1. Parkinson's Disease Trigger Possibly Found

    PharmaGazette - Oct 31, 2007

    Prof. William Burke and his team at Saint Louis University School of Medicine believe that they have uncovered how Parkinson's disease is triggered. Parkinson's happens when a protein called alphasynuclein (AS) clumps …

    Also tagged: research, parkinson s, research and development, dopol, dopal

  2. Parkinson's Disease Trigger Possibly Found [PharmaGazette]

    Know More Media - Health Care / Pharmaceutical / Fitness - Oct 31, 2007

    Prof. William Burke and his team at Saint Louis University School of Medicine believe that they have uncovered how Parkinson's disease is triggered. Parkinson's happens when a protein called alphasynuclein (AS) clumps …

    Also tagged: research, parkinson s, research and development

  3. Abbott Seeks Approval of First Pediatric Indication for Humira®

    PharmaGazette - Jul 10, 2007

    Abbott (NYSE: ABT) has simultaneously submitted regulatory applications for its drug product HUMIRA® (adalimumab): a supplemental Biologics License Application (sBLA) with the USFDA seeking approval to market HUMIRA® …

    Also tagged: abt, eu, abbott, drug regulations and approval, emea, ra, humira, jia, jra

  4. Abbott Seeks Approval of First Pediatric Indication for Humira® [PharmaGazette]

    Know More Media - Health Care / Pharmaceutical / Fitness - May 8, 2007

    Abbott (NYSE: ABT) has simultaneously submitted regulatory applications for its drug product HUMIRA® (adalimumab): a supplemental Biologics License Application (sBLA) with the USFDA seeking approval to market HUMIRA® …

    Also tagged: eu, abbott, drug regulations and approval, emea, ra, humira

  5. Abbott Submitted E.U. and U.S. Regulatory Application for HUMIRA® (Adalimumab) as Psoriasis Treatment [PharmaGazette]

    Know More Media - Health Care / Pharmaceutical / Fitness - Apr 5, 2007

    Abbott (NYSE: ABT) has submitted a supplemental Biologics License Application (sBLA) to the USFDA and a Type II Variation to the EMEA, seeking marketing approval of HUMIRA® (adalimumab) as a treatment for moderate to …

    Also tagged: abbott, autoimmune diseases, drug marketing, drug regulations and approval, ra

  6. REMICADE® Recommended for Approval by EU CHMP for Biologic Treatment of Pediatric Crohn's Disease [PharmaGazette]

    Know More Media - Health Care / Pharmaceutical / Fitness - Mar 29, 2007

    Co-developed by Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP), REMICADE® (infliximab) was first approved in the U.S. ( by the USFDA) in 1998 as treatment U.S. for adult Crohn's disease (CD) and later, in …

    Also tagged: cd, uc, drug regulations and approval, emea, ra, chmp, schering plough corporation